Navigation Links
Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
Date:3/10/2013

o contradictory research findings," said Karl Swedberg, M.D., Ph.D., a senior professor at the Sweden-based Department of Medicine, Sahlgrenska University Hospital and co-investigator of the RED-HF trial. "Our study results show that the use of darbepoetin alfa to stimulate the production of red blood cells is an ineffective treatment for patients with heart failure and anemia."

According to the study, researchers found that darbepoetin alfa treatment led to an early and sustained increase in hemoglobin compared with placebo. However, darbepoetin alfa treatment did not reduce the risk of death from any cause or hospitalization from heart failure. Findings suggest that hemoglobin is a marker of poor prognosis in heart failure, rather than a therapeutic target. There were no new safety findings identified in the study. However, researchers observed an increased risk of thrombosis in the darbepoetin alfa group.

Researchers note that further research is needed to identify treatment options for this patient population.


'/>"/>

Contact: Caroline Auger
augerc@ccf.org
216-296-6012
Cleveland Clinic
Source:Eurekalert

Page: 1 2

Related biology news :

1. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
2. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
3. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
4. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
5. New clinical trial explores novel noninvasive colon cancer screening test
6. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
7. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
8. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
9. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
10. AAO-HNS releases updated Clinical Indicators
11. Sequencing works in clinical setting to help -- finally -- get a diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... a species of alfalfa from Siberia, to the United States. His ... But what also happened during this time in the late ... of the matter is creating a current revival in both interest ... And several researchers members of the American Society of Agronomy (ASA) ...
... 31st, 2012.- Madrid will become international destination for ... Innovation Conference 2012, focused on building high performance ... This new organization has been created by the ... Government of the Comunidad de Madrid, through the ...
... CRUZ, CA--Researchers at the University of California, Santa Cruz, ... from wounds and skin infections, using light to trigger ... developed a photoactive compound that releases nitric oxide when ... biocompatible material that could be applied as a sprayable ...
Cached Biology News:Time is ticking for some crop's wild relatives 2MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012 2Light-induced delivery of nitric oxide eradicates drug-resistant bacteria 2Light-induced delivery of nitric oxide eradicates drug-resistant bacteria 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... leader in,workforce and recruitment solutions announced today that it ... company with its prestigious 2008,Supplier of Excellence Award. ... suppliers, this is the first time they have ever ... are thousands of suppliers of,products and services to Alcon ...
... BioLife Solutions, Inc.,(OTC Bulletin Board: BLFS), a leading ... cryopreservation media products for cells,tissues, and organs, today ... for an application that includes claims related to ... temperatures used in biopreservation. The,patent titled, "Inclusion of ...
... - Data Highlight ... and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine,Acetate) , ... III studies presented today at the,American Epilepsy Society (AES) ... once-daily anti-epileptic,agent, significantly reduced the frequency of partial seizures ...
Cached Biology Technology:Adecco Receives Honor From Alcon Laboratories 2BioLife Solutions Granted European Biopreservation Patent 2Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 2Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 3Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 4Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 5Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 6Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM) 7
... Streptavidin-Horseradish Peroxidase Conjugate, 2 ... reporter enzyme molecules for ... in situ hybridization applications.High ... & Labeling & Detection, ...
...
... Dissociation Buffers are membrane-filtered isotonic and ... agents and cell-conditioning agents in either ... solution or Ca2+- and Mg2+-free ... mammalian cells from support substrates and ...
... Cell Dissociation Buffers are membrane-filtered isotonic ... chelating agents and cell-conditioning agents in ... salt solution or Ca2+- and ... of mammalian cells from support substrates ...
Biology Products: